The possible protective role of glucagon-like peptide1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes

Diabetes Care

Volumn 34, Issue 3, 2011, Pages 697-702

  Ceriello, Antonio ^a   Esposito, Katherine ^b   Testa, Roberto ^c   Bonfigli, Anna Rita ^c   Marra, Maurizio ^c   Giugliano, Dario ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c INRCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL RESISTANCE; FATTY ACID BLOOD LEVEL; FLOW MEDIATED VASODILATION; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; MEAL; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; VASCULAR RESISTANCE;

DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; TYROSINE; VASODILATION;

EID: 79956119675     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1949     Document Type: Article

References (21)

1. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001;142:521-527 (Pubitemid 32222398)
2. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1-7
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809 (Pubitemid 23132154)
4. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010;123(Suppl.):S28-S37
5. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010;59:1117-1125
6. Mudaliar S, Henry RR. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 2010;123(Suppl.):S19-S27
7. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-E1215 (Pubitemid 39491964)
8. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-485 (Pubitemid 9254048)
9. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010;30:1407-1414
10. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57:678-687
11. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223 (Pubitemid 9249478)
12. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-307 (Pubitemid 23037285)
13. Ceriello A, Mercuri F, Quagliaro L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001;44:834-838 (Pubitemid 32642455)
14. Corretti MC, Anderson TJ, Benjamin EJ, et al.; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265 (Pubitemid 34084631)
15. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-154
16. Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 2007;30:649-654 (Pubitemid 46357401)
17. Højberg PV, Vilsbøll T, Zander M, et al. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with type 2 diabetes. Diabet Med 2008;25:1268-1275
18. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol 2009;53(Suppl.):S14-S20
19. Srinivasan M, Herrero P, McGill JB, et al. The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetesmellitus. J Am Coll Cardiol 2005;46:42-48 (Pubitemid 40905127)
20. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002;105:576-582 (Pubitemid 34123431)
21. Campia U, Sullivan G, Bryant MB, Waclawiw MA, Quon MJ, Panza JA. Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. Am J Physiol Heart Circ Physiol 2004;286:H76-H82 (Pubitemid 38049465)